Prime Medicine, Inc.
PRME · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $2 |
| % Growth | 9.9% | -23.3% | -33.4% | – |
| Cost of Goods Sold | $44 | $2 | $0 | $0 |
| Gross Profit | -$43 | -$1 | $1 | $2 |
| % Margin | -3,491% | -67.2% | 100% | 100% |
| R&D Expenses | $44 | $41 | $41 | $34 |
| G&A Expenses | $11 | $13 | $13 | $12 |
| SG&A Expenses | $11 | $13 | $13 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$44 | -$2 | $0 | $0 |
| Operating Expenses | $11 | $53 | $54 | $46 |
| Operating Income | -$54 | -$53 | -$52 | -$44 |
| % Margin | -4,406% | -4,787.2% | -3,603.3% | -2,025.7% |
| Other Income/Exp. Net | $3 | $1 | $1 | $2 |
| Pre-Tax Income | -$51 | -$53 | -$52 | -$42 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$51 | -$53 | -$52 | -$42 |
| % Margin | -4,129.1% | -4,716.7% | -3,568.8% | -1,936.6% |
| EPS | -0.32 | -0.407 | -0.397 | -0.357 |
| % Growth | 21.4% | -2.7% | -11.2% | – |
| EPS Diluted | -0.32 | -0.407 | -0.397 | -0.357 |
| Weighted Avg Shares Out | 161 | 129 | 131 | 119 |
| Weighted Avg Shares Out Dil | 161 | 129 | 131 | 119 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | -$49 | -$52 | -$51 | -$43 |
| % Margin | -3,975.6% | -4,620% | -3,486.4% | -1,947.1% |